Amphastar Pharmaceuticals (29A) AI Stock Analysis

2 Followers

Amphastar Pharmaceuticals

(Frankfurt:29A)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Portfolio GrowthRecord revenue and contributions from multiple products indicate broad commercial traction rather than reliance on a single launch. Continued growth in BAQSIMI, Primatene MIST, ipratropium bromide and teriparatide can support durable portfolio expansion over the next several quarters.

Negative Factors

Margin and Pricing PressureLower selling prices and higher costs are weakening profitability even while revenue grows. Persistent BAQSIMI rebates and discounting could limit margin recovery, reducing the earnings contribution from an important product and constraining reinvestment capacity.

Amphastar Pharmaceuticals (29A) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.22B
Dividend Yield: ―
Average Volume (3M): 61
Price to Earnings (P/E): 12.7
Beta (1Y): 0.58
Revenue Growth: -1.94%
EPS Growth: -9.38%
Country: Germany
Employees: 1,976
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Amphastar Pharmaceuticals Business Overview & Revenue Model

Company Description

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and p...

Amphastar Pharmaceuticals Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:5.47%|Next Earnings Date:Mar 04, 2027

Earnings Call SentimentPositive

The call was broadly positive, supported by record revenue, record BAQSIMI and Primatene MIST sales, improved net income and adjusted earnings, progress on pipeline programs, and additional shareholder-return authorization. These positives were tempered by lower gross margin, persistent BAQSIMI pricing pressure, declines in epinephrine and glucagon, and ongoing IMS remediation costs, release delays, and backlog. Overall, the highlights significantly outweighed the lowlights.

Positive Updates

Record Quarterly Revenue

Third-quarter revenue reached a record $207.6 million, increasing approximately 8% year-over-year from $191.8 million and 13% sequentially. Growth was driven primarily by BAQSIMI and Primatene MIST, supplemented by recently launched products.

Negative Updates

Gross Margin Declined

Cost of revenues increased 16% to $108 million from $93.2 million, while gross margin decreased to 48% from 51%. The primary drivers were lower average selling prices for BAQSIMI, glucagon, and the epinephrine multi-dose vial product, along with higher IMS remediation-related manufacturing expenses.

Company Guidance

For the fourth quarter, management expects sales to increase in the high single-digit range compared to the fourth quarter of last year, incorporating a modest slowdown in IMS sales; IMS remediation expense was probably between $2 million and $3 million in the third quarter and will probably be a little bit higher than that in each of the next two or three quarters. Management is not prepared to give guidance for 2027, but expects strong growth from BAQSIMI, growth from Primatene MIST, and annualized sales of ipratropium bromide; it also expects lidocaine demand to continue into next year, API sales to continue around the same level, and strong teriparatide sales, although it may not get growth out of that. The insulin biosimilar is expected to launch next year, but there is no firm date, while AMP-018 is expected to have a limited opportunity due to the competitive nature of that environment and remains on track for the 2027 commercialization; the company’s goal is to file AMP-104 by the end of 2028.

Amphastar Pharmaceuticals Risk Analysis

Amphastar Pharmaceuticals disclosed 86 risk factors in its most recent earnings report. Amphastar Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Amphastar Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:29A against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANIP	72Outperform	$1.64B	13.72	20.00%	―	25.94%	203.25%
PCRX	66Neutral	$1.46B	38.29	5.53%	―	3.70%	101.62%
TEVA	65Neutral	$49.58B	101.81	9.18%	―	2.99%	-28.63%
AMRX	58Neutral	$7.45B	50.49	131.71%	―	8.88%	2272.07%
VTRS	58Neutral	$23.90B	-39.73	-4.24%	2.28%	4.80%	82.97%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:29A and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:29A	Amphastar Pharmaceuticals Inc	25.65	2.09	8.87%
VTRS	Viatris, Inc.	21.06	10.52	99.89%
PCRX	Pacira	36.46	12.84	54.36%
TEVA	Teva Pharmaceutical Industries Limited	43.24	17.24	66.31%
ANIP	Ani Pharmaceuticals	71.09	-13.46	-15.92%
AMRX	Amneal Pharma	21.71	10.19	88.45%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Amphastar Pharmaceuticals AI Stock Analysis